

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)



ATTY. DOCKET NO.
QA0239ACIP
APPLICATION NO.
09/891,750
APPLICANT
MORIARTY ET AL.
FILING DATE
JUNE 26, 2001

Group 1624

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
W	AA	5,840,893	11/24/98	Bukrinsky et al.	544	329	
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION YES NO
W	AM	EP834,507	4/8/98	Europe			<input type="checkbox"/> <input type="checkbox"/>
W	AN	EP969004	1/5/00	Europe			<input type="checkbox"/> <input type="checkbox"/>
W	AO	WO95/30642	11/16/95	PCT			<input type="checkbox"/> <input type="checkbox"/>
W	AP	WO98/24782	6/11/98	PCT			<input type="checkbox"/> <input type="checkbox"/>
W	AQ	WO99/01442	1/14/99	PCT			<input type="checkbox"/> <input type="checkbox"/>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

W	AR	Fujiwara et al., Bioorganic & Medicinal Chemistry Letters, Vol. 10, p. 1317 - 1320 (2000)
W	AS	Raingeaud et al., Molecular And Cellular Biology, Vol. 16, No. 3, p. 1247 - 1255 (March 1996)
W	AT	Henry et al., Drugs and the Future, Vol. 24 (12), p. 1345 - 1354 (1999)

EXAMINER


V. Balasubramanian

DATE CONSIDERED

6/12/02

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

(Use several sheets if necessary)

ATTY. DOCKET NO.
QA0239ACIP
APPLICATION NO.
09/891,750
APPLICANT
MORIARTY ET AL.
FILING DATE
JUNE 26, 2001

Group 1624

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

✓	AA	Resnihan et al., Arthritis & Rheumatism, Vol. 41, No. 12, p. 2196 - 2204 (Dec. 1998)
✓	AB	Moreland et al., Annals of Internal Medicine, Vol. 130, No. 6, p. 478 - 486 (March 1999)
✓	AC	Bundgaard, Advanced Drug Delivery Reviews, Vol. 3, p. 39 - 65 (1989)
✓	AD	Sabituro et al., Current Medicinal Chemistry, Vol. 6, p. 807 - 823 (1999)
✓	AE	Rankin et al., British Journal of Rheumatology, Vol. 34, p. 334 - 342 (1995)
✓	AF	Kotlyarov et al., Nature Cell Biology, Vol. 1, p. 94- 97 (1999)
✓	AG	Bodor et al., Annual Reports In Medicinal Chemistry, Vol. 22, p. 303 - 313 (1987)
	AH	
	AI	
	AJ	
	AK	
	AL	
	AM	
	AN	

EXAMINER

DATE CONSIDERED

6/12/02

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.